高级检索
当前位置: 首页 > 详情页

Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: The Pan-Asia menopause (PAM) study

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China [2]China Japan Friendship Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China [3]Yonsei Univ, Dept Obstet & Gynecol, Sinchon Severance Hosp, Sch Med, Seoul 120749, South Korea [4]PharmConsult, New York, NY USA [5]Wyeth Pharmaceut, Collegeville, PA USA
出处:
ISSN:

关键词: pan-Asia menopause study PAM study Asian women hormone therapy vasomotor symptoms vaginal maturation index

摘要:
Objective: To survey the prevalence of 18 menopausal symptoms in nine ethnic groups of Asian women. To evaluate responsiveness of symptoms to three estrogen/progestin doses in Asian women. Design: A prospective, randomized, double-blind multinational clinical trial in 1028 healthy postmenopausal women from I I Asian countries/regions. Following 2 weeks of baseline observations, the women received one of three conjugated estrogens (CE)/medroxyprogesterone acetate (MPA) doses (in mg) daily for 24 weeks: 0.625/2.5; 0.45/1.5; or 0.3/1.5. At baseline and throughout the study period, the women were asked to record each symptom daily on diary cards translated into 10 languages. Results: The number of women in the different ethnic groups ranged from 24 (Malay) to 248 (Chinese). The overall prevalence of symptoms differed among the groups, with Vietnamese women generally reporting the highest rates. Within each ethnic group, the prevalence of individual symptoms varied substantially. Only 5% of Indonesian women, for example, reported hot flushes but 93% complained of body or joint aches/pains. Overall, body or joint aches/pains was the most prevalent symptom, ranging from 76% in Korean women to 96% in Vietnamese women. Therapy resulted in a significant decline in all symptoms. The decline was observed with all three doses after 4 weeks of treatment and continued throughout the 6-month study period. Conclusion: The prevalence of individual menopausal symptoms differed among ethnic groups of Asian women. Within each ethnic group the percentage of women reporting each symptom varied substantially. Symptoms declined after 4 weeks of hormone therapy and thereafter throughout the study. The effect of the lowest dose of CE/MPA (0.3/1.5 mg/day) was comparable to that of the higher doses. (c) 2005 Elsevier Ireland Ltd. All fights reserved.

语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2004]版:
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 妇产科学 3 区 老年医学
JCR分区:
出版当年[2003]版:
Q1 OBSTETRICS & GYNECOLOGY Q2 GERIATRICS & GERONTOLOGY
最新[2023]版:
Q1 OBSTETRICS & GYNECOLOGY Q2 GERIATRICS & GERONTOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2003版] 出版当年五年平均[1999-2003] 出版前一年[2002版] 出版后一年[2004版]

第一作者:
第一作者单位: [1]Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]A multicenter, randomized, open, controlled trial to evaluate the efficacy of Honglilai Vaginal Cream and Premarin Vaginal Cream for Genitourinary Syndrome of Menopause in different subgroups of Chinese postmenopausal women [2]Meta-analysis of metabolic changes in children with idiopathic growth hormone deficiency after recombinant human growth hormone replacement therapy [3]A meta-analysis of combination therapy with gonadotrophin-releasing hormone agonist and growth hormone for children with idiopathic short stature and normal timed puberty [4]Association Between Recombinant Growth Hormone Therapy and All-Cause Mortality and Cancer Risk in Childhood: Systematic Review and Meta-Analysis [5]Efficacy of Pulsatile Gonadotropin-Releasing Hormone Therapy in Male Patients: Comparison between Pituitary Stalk Interruption Syndrome and Congenital Hypogonadotropic Hypogonadism. [6]A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin [7]Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial [8]Preservation of renal function by thyroid hormone replacement in elderly persons with subclinical hypothyroidism [9]Microwave ablation versus radiofrequency ablation for primary hyperparathyroidism: a multicenter retrospective study [10]A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC)

资源点击量:1320 今日访问量:0 总访问量:817 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)